Science Explorer Back to mapMap

Most cited papers from Basilea Pharmaceutica (Switzerland)

What are the most cited papers from Basilea Pharmaceutica (Switzerland)?

The most cited paper from Basilea Pharmaceutica (Switzerland) is "Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial" (Johan A. Maertens et al., 2015), with 1,006 citations. Next come "Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis" (710) and "Identification of an antimalarial synthetic trioxolane drug development candidate" (624).

Showing 50 of 60 papers. Every paper with more than 72 citations is listed.

Most cited papers, sortable by citations and release date
#Paper
1 Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial Johan A. Maertens et al. · The Lancet 15 Dec 2015 1,006
2 Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis Francisco M. Marty et al. · The Lancet Infectious Diseases 8 Mar 2016 710
3 Identification of an antimalarial synthetic trioxolane drug development candidate Jonathan L. Vennerstrom, Sarah Arbe‐Barnes, Reto Brun et al. · Nature Aug 2004 624
4 Efficacy and safety of oral alitretinoin (9-cis retinoic acid) in patients with severe chronic hand eczema refractory to topical corticosteroids: results of a randomized, double-blind, placebo-controlled, multicentre trial Thomas Ruzicka, Charles W Lynde, Gregor B. E. Jemec et al. · British Journal of Dermatology 21 Feb 2008 412
5 Dual Inhibition of the Lactate Transporters MCT1 and MCT4 Is Synthetic Lethal with Metformin due to NAD+ Depletion in Cancer Cells Don Benjamin, Dimitri Robay, Sravanth Kumar Hindupur et al. · Cell Reports Open access Dec 2018 404
6 Synthetic ozonide drug candidate OZ439 offers new hope for a single-dose cure of uncomplicated malaria Susan A. Charman et al. · Proceedings of the National Academy of Sciences Open access 7 Feb 2011 383
7 The Novel Microtubule-Destabilizing Drug BAL27862 Binds to the Colchicine Site of Tubulin with Distinct Effects on Microtubule Organization Andrea Enrico Prota, Franck Danel, Felix Bachmann et al. · Journal of Molecular Biology 11 Feb 2014 314
8 mTOR Inhibitor RAD001 (Everolimus) Has Antiangiogenic/Vascular Properties Distinct from a VEGFR Tyrosine Kinase Inhibitor Heidi A. Lane, Jeanette Marjorie Wood, Paul M.J. McSheehy et al. · Clinical Cancer Research Open access 17 Feb 2009 254
9 A Phase 3 Randomized Double-Blind Comparison of Ceftobiprole Medocaril Versus Ceftazidime Plus Linezolid for the Treatment of Hospital-Acquired Pneumonia Samir Sayed Hassan Awad, Alejandro H. Rodríguez, Yin-Ching Chuang et al. · Clinical Infectious Diseases Open access 9 Apr 2014 231
10 In Vitro Properties of BAL30072, a Novel Siderophore Sulfactam with Activity against Multiresistant Gram-Negative Bacilli Malcolm G. P. Page, Clothilde Dantier, Eric Desarbre · Antimicrobial Agents and Chemotherapy Open access 23 Mar 2010 227
11 Isavuconazole Treatment of Cryptococcosis and Dimorphic Mycoses George R. Thompson, Adrián Rendón, Rodrigo Ribeiro dos Santos et al. · Clinical Infectious Diseases Open access 11 May 2016 224
12 In Vitro and In Vivo Properties of Ro 63-9141, a Novel Broad-Spectrum Cephalosporin with Activity against Methicillin-Resistant Staphylococci Paul Hebeisen, Ingrid Heinze‐Krauss, Peter Angehrn et al. · Antimicrobial Agents and Chemotherapy Open access Mar 2001 218
13 Identifying Optimal Biologic Doses of Everolimus (RAD001) in Patients With Cancer Based on the Modeling of Preclinical and Clinical Pharmacokinetic and Pharmacodynamic Data Chiaki Tanaka, Terence O’Reilly, John M. Kovarik et al. · Journal of Clinical Oncology 11 Mar 2008 211
14 Results of a Double-Blind, Randomized Trial of Ceftobiprole Treatment of Complicated Skin and Skin Structure Infections Caused by Gram-Positive Bacteria Gary J. Noel, Richard S Strauss, Karen M. Amsler et al. · Antimicrobial Agents and Chemotherapy Open access 22 Oct 2007 191
15 Interaction of antibacterial compounds with RND efflux pumps in Pseudomonas aeruginosa Jürg Dreier, Paolo Ruggerone · Frontiers in Microbiology Open access 8 Jul 2015 188
16 Isavuconazole Versus Caspofungin in the Treatment of Candidemia and Other Invasive Candida Infections: The ACTIVE Trial Bart Jan Kullberg, Claudio Viscoli, Peter G. Pappas et al. · Clinical Infectious Diseases Open access 4 Oct 2018 185
17 Antistaphylococcal Activity of Ceftobiprole, a New Broad-Spectrum Cephalosporin Tatiana Bogdanovich, Lois M. Ednie, Stuart Shapiro et al. · Antimicrobial Agents and Chemotherapy Open access 27 Sep 2005 185
18 Single-Ascending-Dose Pharmacokinetics and Safety of the Novel Broad-Spectrum Antifungal Triazole BAL4815 after Intravenous Infusions (50, 100, and 200 Milligrams) and Oral Administrations (100, 200, and 400 Milligrams) of Its Prodrug, BAL8557, in Healthy Volunteers Anne H. Schmitt‐Hoffmann, Brigitte Roos, Markus Heep et al. · Antimicrobial Agents and Chemotherapy Open access 23 Dec 2005 170
19 Binding of Ceftobiprole and Comparators to the Penicillin-Binding Proteins of Escherichia coli , Pseudomonas aeruginosa , Staphylococcus aureus , and Streptococcus pneumoniae Todd A. Davies, Malcolm G. P. Page, Wenchi Shang et al. · Antimicrobial Agents and Chemotherapy Open access 30 Apr 2007 166
20 Detection of circulating tumour cell clusters in human glioblastoma Ilona Krol, Francesc Castro-Giner, Martina Maurer et al. · British Journal of Cancer Open access 19 Jul 2018 145
21 Multiple-Dose Pharmacokinetics and Safety of the New Antifungal Triazole BAL4815 after Intravenous Infusion and Oral Administration of Its Prodrug, BAL8557, in Healthy Volunteers Anne H. Schmitt‐Hoffmann, Brigitte Roos, J. Maares et al. · Antimicrobial Agents and Chemotherapy Open access 23 Dec 2005 141
22 Oral Alitretinoin (9-cis-Retinoic Acid) Therapy for Chronic Hand Dermatitis in Patients Refractory to Standard Therapy Thomas Ruzicka, Frederik Grønhøj Larsen, Dorota Galewicz et al. · Archives of Dermatology Dec 2004 135
23 Drug‐drug interactions between triazole antifungal agents used to treat invasive aspergillosis and immunosuppressants metabolized by cytochrome P450 3A4 Andreas H. Groll, Robert W. Townsend, Amit V. Desai et al. · Transplant Infectious Disease Open access 19 Jul 2017 134
24 The Burden and Impact of Vertigo: Findings from the REVERT Patient Registry Heike Benecke, Sam Agus, Daniel Kuessner et al. · Frontiers in Neurology Open access 2013 132
25 Klebsiella pneumoniae Carbapenemase-2 (KPC-2), Substitutions at Ambler Position Asp179, and Resistance to Ceftazidime-Avibactam: Unique Antibiotic-Resistant Phenotypes Emerge from β-Lactamase Protein Engineering Melissa D. Barnes, Marisa Winkler, Magdalena A. Taracila et al. · mBio Open access 31 Oct 2017 131
26 The Innovative Medicines Initiative's New Drugs for Bad Bugs programme: European public–private partnerships for the development of new strategies to tackle antibiotic resistance Tomislav Kostyanev, Marc J. M. Bonten, Seamus O’Brien et al. · Journal of Antimicrobial Chemotherapy Open access 15 Nov 2015 129
27 Impact of Specific pbp5 Mutations on Expression of β-Lactam Resistance in Enterococcus faecium Louis B. Rice, Samuel Bellais, Lenore L. Carias et al. · Antimicrobial Agents and Chemotherapy Open access 23 Jul 2004 128
28 Structure and Function of the PiuA and PirA Siderophore-Drug Receptors from Pseudomonas aeruginosa and Acinetobacter baumannii L. Moynié, Alexandre Lüscher, Dora Rolo et al. · Antimicrobial Agents and Chemotherapy Open access 30 Jan 2017 126
29 Prospects for the next anti-Pseudomonas drug Malcolm G. P. Page, Jutta Heim · Current Opinion in Pharmacology 13 Sep 2009 126
30 NutriChip: nutrition analysis meets microfluidics Qasem Ramadan, Hamideh Jafarpoorchekab, Chaobo Huang et al. · Lab on a Chip Open access 27 Nov 2012 123
31 Siderophore conjugates Malcolm G. P. Page · Annals of the New York Academy of Sciences 2013 122
32 Safety and Pharmacokinetics of Isavuconazole as Antifungal Prophylaxis in Acute Myeloid Leukemia Patients with Neutropenia: Results of a Phase 2, Dose Escalation Study Oliver A. Cornely, Angelika Böhme, Anne H. Schmitt‐Hoffmann et al. · Antimicrobial Agents and Chemotherapy Open access 27 Jan 2015 116
33 Ceftobiprole for Treatment of Complicated Staphylococcus aureus Bacteremia Thomas L Holland et al. · New England Journal of Medicine Open access 27 Sep 2023 113
34 Pharmacokinetic Evaluation of CYP3A4‐Mediated Drug‐Drug Interactions of Isavuconazole With Rifampin, Ketoconazole, Midazolam, and Ethinyl Estradiol/Norethindrone in Healthy Adults Robert W. Townsend, Albert G. H. Dietz, Christine Hale et al. · Clinical Pharmacology in Drug Development Open access 8 Jun 2016 113
35 Crystallographic and Biophysical Analysis of a Bacterial Signal Peptidase in Complex with a Lipopeptide-based Inhibitor Mark Paetzel, Jonathon J. Goodall, Malgosia Kania et al. · Journal of Biological Chemistry Open access Jul 2004 109
36 Pharmacokinetics and Pharmacodynamics of Ceftobiprole, an Anti-MRSA Cephalosporin with Broad-Spectrum Activity Bindu Murthy, Anne H. Schmitt‐Hoffmann · Clinical Pharmacokinetics 2008 109
37 Structural Insights into the Anti-methicillin-resistant Staphylococcus aureus (MRSA) Activity of Ceftobiprole Andrew L. Lovering, Michael C. Gretes, Susan S. Safadi et al. · Journal of Biological Chemistry Open access 20 Jul 2012 108
38 The Structure−Activity Relationship of the Antimalarial Ozonide Arterolane (OZ277) Yuxiang Dong, Sergio Wittlin, Kamaraj Sriraghavan et al. · Journal of Medicinal Chemistry 19 Nov 2009 108
39 Successful retreatment with alitretinoin in patients with relapsed chronic hand eczema Robert Bissonnette, Margitta Worm, B. Gerlach et al. · British Journal of Dermatology 10 Nov 2009 105
40 Single-Dose Pharmacokinetics and Safety of a Novel Broad-Spectrum Cephalosporin (BAL5788) in Healthy Volunteers Anne H. Schmitt‐Hoffmann, Brigitte Roos, Michael Schleimer et al. · Antimicrobial Agents and Chemotherapy Open access 23 Jun 2004 103
41 BAL9141, a Novel Extended-Spectrum Cephalosporin Active against Methicillin-Resistant Staphylococcus aureus in Treatment of Experimental Endocarditis Jose Manuel Entenza, P. Hohl, Ingrid Heinze‐Krauss et al. · Antimicrobial Agents and Chemotherapy Open access 2002 91
42 Engineering specificity of starter unit selection by the erythromycin‐producing polyketide synthase Paul F. Long, Christopher J. Wilkinson, Christian Bisang et al. · Molecular Microbiology Mar 2002 90
43 Isavuconazole for the treatment of patients with invasive fungal diseases involving the central nervous system Stefan Schwartz, Oliver A. Cornely, Kamal A. Hamed et al. · Medical Mycology Open access 2 Oct 2019 89
44 Antimicrobial and DNA Gyrase-Inhibitory Activities of Novel Clorobiocin Derivatives Produced by Mutasynthesis Ute Galm, Stefanie Heller, Stuart Shapiro et al. · Antimicrobial Agents and Chemotherapy Open access 26 Mar 2004 89
45 Interactions of Ceftobiprole with β-Lactamases from Molecular Classes A to D Anne Marie Queenan, Wenchi Shang, Malgosia Kania et al. · Antimicrobial Agents and Chemotherapy Open access 26 Jun 2007 87
46 Syrosingopine sensitizes cancer cells to killing by metformin Don Benjamin, Marco Colombi, Sravanth Kumar Hindupur et al. · Science Advances Open access 2 Dec 2016 83
47 A lipid-mediated conformational switch modulates the thermosensing activity of DesK María Eugenia Inda, Michel Vandenbranden, Ariel Fernández et al. · Proceedings of the National Academy of Sciences Open access 12 Feb 2014 82
48 Multiple-Dose Pharmacokinetics and Safety of a Novel Broad-Spectrum Cephalosporin (BAL5788) in Healthy Volunteers Anne H. Schmitt‐Hoffmann, Lars Nyman, Brigitte Roos et al. · Antimicrobial Agents and Chemotherapy 23 Jun 2004 79
49 Involvement of the Putative ATP-Dependent Efflux Proteins PatA and PatB in Fluoroquinolone Resistance of a Multidrug-Resistant Mutant of Streptococcus pneumoniae Estelle Marrer, Karen Schad, Andreas T. Satoh et al. · Antimicrobial Agents and Chemotherapy Open access 25 Jan 2006 79
50 Molecular Basis of Filtering Carbapenems by Porins from β-Lactam-resistant Clinical Strains of Escherichia coli Harsha Bajaj, Mariano Andrea Scorciapino, L. Moynié et al. · Journal of Biological Chemistry Open access 9 Dec 2015 78

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.